Cadrenal Therapeutics, a heart-focused biotech that recently reached an agreement with the FDA on the design of a pivotal ...

TCGX is expanding its operations to Asia in connection with the fund, opening offices in Shanghai and Hong Kong. Dandan Dong, ...

Caribou Biosciences, the off-the-shelf cell therapy outfit that spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, is ...

Stryker veteran Spencer Stiles will take up the chief executive role as its former CEO Kevin Lobo will move into the ...

The U.S. Department of Health and Human Services announced the launching of a new program aimed to remove barriers that slow clinical development and transform how clinical trials are designed and ...

Matchpoint Therapeutics has aced its series B round, serving up $150 million to advance the Sanofi-backed biotech’s pipeline ...

MimiVax's cancer vaccine missed the primary endpoint of a phase 2 study in patients with newly diagnosed glioblastoma, although the biotech claimed it can still see a path forward for the candidate | ...

Atsena expects to complete enrollment in the third part of the Lighthouse study next year. (den-belitsky/iStock/ Plus) Atsena Therapeutics has reported evidence of efficacy in a clinical trial of an ...

Big Pharma-backed Nuvig Therapeutics has halted one of two trials for its sole clinical asset after determining the program ...

Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for ...

A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57% in early trading.

Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver ...